The latest work from the research team of NeuroQuest Founder and Chief Scientist, Dr. Michal Schwartz, published in Nature Medicine was highlighted in the U.K. Telegraph showing the potential certain cancer-fighting drugs may have in fighting Alzheimer’s disease.
“We are extremely excited about our new study, we believe it is a game changer both conceptually and therapeutically,” Dr. Schwartz said. “There is currently no cure or disease-modifying treatment for Alzheimer’s disease, and the prospect of using PD-1 blockers, may suggest short translation to the clinic.”
“Systemic immune suppression may curtail the ability to mount the protective, cell-mediated immune responses that are needed for brain repair. By using mouse models of Alzheimer’s disease (AD), we show that immune checkpoint blockade directed against the programmed death-1 (PD-1) pathway evokes an interferon (IFN)-g–dependent systemic immune response, which is followed by the recruitment of monocyte- derived macrophages to the brain. When induced in mice with established pathology, this immunological response leads to clearance of cerebral amyloid-b (Ab) plaques and improved cognitive performance. Repeated treatment sessions were required to maintain a long-lasting beneficial effect on disease pathology. These findings suggest that immune checkpoints may be targeted therapeutically in AD.”
The full article can be found in Nature Medicine, courtesy of the Nature Medicine-U.K. Telegraph sharing initiative.